Clinical Trial

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

Study acronym: PASTORALE
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
Protocol Amendment History 5 changes
notable Enrollment increased: 165 -> 325 participants 2026-08-12
notable Trial sites expanded: 58 -> 62 locations 2026-08-12
notable Trial sites expanded: 52 -> 56 locations 2026-05-20
notable Trial sites expanded: 46 -> 50 locations 2026-04-18
notable Trial sites expanded: 34 -> 46 locations 2026-04-01
Trial Details
NCT Number NCT07010159
Lead Sponsor Kiniksa Pharmaceuticals International, plc
Collaborators: Kiniksa Pharmaceuticals, GmbH
Conditions Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Enrollment 325 participants
Start Date 2025-07-25
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11